HilleVax
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 90
- Market Cap
- $96M
- Website
- http://www.hillevax.com
- Introduction
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- HilleVax
- Target Recruit Count
- 21
- Registration Number
- NCT06007781
- Locations
- 🇯🇵
Fukui Aiiku Hospital, Fukui-Shi, Japan
🇯🇵Iizuka Children's Clinic, Iizuka-Shi, Japan
🇯🇵Childrens Clinic of Kose, Kofu-Shi, Japan
Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- HilleVax
- Target Recruit Count
- 80
- Registration Number
- NCT05972733
- Locations
- 🇺🇸
Pennisula Research Associates, Rolling Hills Estates, California, United States
🇺🇸Clinical Research Atlanta, Stockbridge, Georgia, United States
Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- HilleVax
- Target Recruit Count
- 329
- Registration Number
- NCT05836012
- Locations
- 🇺🇸
Velocity Clinical Research - Lafayette, Lafayette, Louisiana, United States
🇺🇸Boeson Research MSO, Missoula, Montana, United States
🇺🇸Velocity Clinical Research - Hastings, Hastings, Nebraska, United States
Efficacy and Safety of Two Doses of HIL-214 in Children
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- HilleVax
- Target Recruit Count
- 3084
- Registration Number
- NCT05281094
- Locations
- 🇺🇸
DM Clinical Research, Houston, Texas, United States
🇨🇴Policlinico Social del Norte, Bogotá, Distrito Capital, Colombia
🇨🇴Cntro de Estudios en Infectologia Pediatrica (CEIP), Cali, Valle Del Cauca, Colombia
News
XOMA Royalty Acquires Mural Oncology for $36.2 Million in Strategic Biotech Consolidation
XOMA Royalty's subsidiary XRA 5 Corp. will acquire clinical-stage immuno-oncology company Mural Oncology for $2.035 per share base price, potentially reaching $36.2 million total value.
Xoma Royalty Acquires Mural Oncology for $35.2-38.8M in Latest Biotech Liquidation Deal
Xoma Royalty Corp. agreed to acquire Mural Oncology for $2.035-2.240 per share, valuing the deal at $35.2-38.8 million depending on closing cash balance.